


RECEIVED  
CENTRAL FAX CENTER  
JUL 13 2006

Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

# AMENDMENTS TO THE CLAIMS

Please replace all prior versions and listings of claims with the amended claims as follows:

1. (Previously presented) A compound of formula I:



or a pharmaceutically acceptable salt thereof, wherein:

$W^1$  is nitrogen or CH,  $W^2$  is nitrogen or  $C-(J)_pR^U$ , and  $W^3$  is nitrogen or  $C-(V)_qR^V$ ;

$p$  and  $q$  are each independently 0 or 1;

$R^U$  and  $R^V$  are each independently R or  $Ar^1$ ;

$U$  and  $V$  are each independently a bond or a  $C_{1-6}$  alkylidene chain, wherein up to two methylene units of the chain are optionally and independently replaced by CO,  $CO_2$ , COCO, CONR, OCONR, NRNR, NRNRCO, NRCO,  $NRCO_2$ , NRCONR, SO,  $SO_2$ ,  $NRSO_2$ ,  $SO_2NR$ ,  $NRSO_2NR$ , O, S, or NR;


each occurrence of R is independently hydrogen or an optionally substituted  $C_1-C_4$  aliphatic, or two R bound to the same nitrogen atom are optionally taken together with the nitrogen atom to form a 3-7 membered saturated, partially unsaturated, or fully unsaturated ring having 0-2 additional heteroatoms independently selected from nitrogen, oxygen, or sulfur;

$Ar^1$  is a 5-7 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or

Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936

sulfur; wherein  $\text{Ar}^1$  is optionally substituted with  $m$  independent occurrences of  $\text{Z-R}^5$ ; wherein  $m$  is 0-5,  $\text{Z}$  is a bond or is a  $\text{C}_1\text{-C}_6$  alkylidene chain wherein up to two methylene units of  $\text{Z}$  are optionally replaced by  $\text{CO}$ ,  $\text{CO}_2$ ,  $\text{COCO}$ ,  $\text{CONR}$ ,  $\text{OCONR}$ ,  $\text{NRNR}$ ,  $\text{NRNRCO}$ ,  $\text{NRCO}$ ,  $\text{NRCO}_2$ ,  $\text{NRCONR}$ ,  $\text{SO}$ ,  $\text{SO}_2$ ,  $\text{NRSO}_2$ ,  $\text{SO}_2\text{NR}$ ,  $\text{NRSO}_2\text{NR}$ ,  $\text{O}$ ,  $\text{S}$ , or  $\text{NR}$ ; and each occurrence of  $\text{R}^5$  is independently hydrogen, an optionally substituted aliphatic, heteroaliphatic, aryl or heteroaryl group, halogen,  $\text{NO}_2$ ,  $\text{CN}$ ,  $\text{OR}$ ,  $\text{SR}$ ,  $\text{N(R)}_2$ ,  $\text{NRCOR}$ ,  $\text{NRCON(R)}_2$ ,  $\text{NRCO}_2\text{R}$ ,  $\text{COR}$ ,  $\text{CO}_2\text{R}$ ,  $\text{OCOR}$ ,  $\text{CON(R)}_2$ ,  $\text{OCON(R)}_2$ ,  $\text{SOR}$ ,  $\text{SO}_2\text{R}$ ,  $\text{SO}_2\text{N(R)}_2$ ,  $\text{NRSO}_2\text{R}$ ,  $\text{NRSO}_2\text{N(R)}_2$ ,  $\text{COCOR}$ , or  $\text{COCH}_2\text{COR}$ ;

$\text{R}^1$  and  $\text{R}^2$  are taken together and fused to ring B to form a heterocyclic moiety selected from one of formulae (a) through (f):



wherein each occurrence of  $\text{R}^X$  is independently hydrogen,  $\text{QR}$ , or  $\text{Q}_n\text{Ar}^1$ ;  $n$  is zero or one; and  $\text{Q}$  is an optionally substituted  $\text{C}_{1-4}$  alkylidene chain wherein one methylene unit of  $\text{Q}$  is optionally replaced by  $\text{CO}$ ,  $\text{CO}_2$ ,  $\text{COCO}$ ,  $\text{CONR}$ ,  $\text{OCONR}$ ,  $\text{NRNR}$ ,  $\text{NRNRCO}$ ,  $\text{NRCO}$ ,  $\text{NRCO}_2$ ,  $\text{NRCONR}$ ,  $\text{SO}$ ,  $\text{SO}_2$ ,  $\text{NRSO}_2$ ,  $\text{SO}_2\text{NR}$ ,  $\text{NRSO}_2\text{NR}$ ,  $\text{O}$ ,  $\text{S}$ , or  $\text{NR}$ ;  
 $\text{R}^3$  is hydrogen, halogen,  $\text{QR}$ ,  $\text{Q}_n\text{CN}$ ,  $\text{Q}_n\text{NO}_2$ , or  $\text{Q}_n\text{Ar}^1$ ; and  
 $\text{R}^4$  is  $\text{Ar}^1$ , or  $\text{T-Ar}^1$ ;

Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

wherein T is a C<sub>1-2</sub> alkylidene chain wherein one methylene unit of T is optionally replaced by CO, CO<sub>2</sub>, COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, NRCO<sub>2</sub>, NRCONR, SO, SO<sub>2</sub>, NRSO<sub>2</sub>, SO<sub>2</sub>NR, NRSO<sub>2</sub>NR, O, S, or NR.

2. (Previously presented) The compound of claim 1, wherein R<sup>1</sup> and R<sup>2</sup> taken together form the heterocyclic moiety of formula (a) and R<sup>X</sup> is hydrogen or optionally substituted C<sub>1-6</sub> aliphatic.
3. (Original) The compound of claim 1, wherein R<sup>X</sup> is hydrogen, methyl, ethyl, propyl, n-butyl, tert-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, C<sub>1-6</sub>alkyl substituted with N(R)<sub>2</sub>, or C<sub>1-6</sub>alkyl substituted with Ar<sup>1</sup>.
4. (Original) The compound of claim 1, wherein R<sup>X</sup> is hydrogen, methyl, or C<sub>1-2</sub>alkyl substituted with a group selected from optionally substituted phenyl, pyridyl, morpholino, piperidinyl, or piperazinyl.
5. (Original) The compound of claim 1, wherein R<sup>3</sup> is hydrogen, halogen, QR or QAr<sup>1</sup>, wherein Q is a C<sub>1-3</sub> alkylidene chain wherein one methylene unit of Q is optionally replaced by -O-, -S-, -NHCO-, or -NR-, and Ar<sup>1</sup> is an optionally substituted 5-6 membered saturated, partially unsaturated, or fully unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
6. (Original) The compound of claim 1, wherein R<sup>3</sup> is hydrogen, OH, OCH<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, NHCOMe, NH<sub>2</sub>, NH(C<sub>1-4</sub> aliphatic), N(C<sub>1-4</sub> aliphatic)<sub>2</sub>, O(CH<sub>2</sub>)<sub>2</sub>morpholin-4-yl, O(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>, O(CH<sub>2</sub>)<sub>2</sub>NH(C<sub>1-4</sub> aliphatic), O(CH<sub>2</sub>)<sub>2</sub>N(C<sub>1-4</sub> aliphatic)<sub>2</sub>, Br, Cl, or F.
7. (Original) The compound of claim 1, wherein R<sup>3</sup> is hydrogen.


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

8. (Original) The compound of claim 1, wherein  $R^4$  is a 6-membered saturated, partially unsaturated, or aryl ring having 0-3 nitrogens; a 9-10 membered bicyclic aryl ring having 0-2 nitrogen atoms, or a 5 membered heteroaryl ring having 2-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein each ring is optionally substituted.
9. (Original) The compound of claim 1, wherein  $R^4$  is optionally substituted phenyl, cyclohexyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, thiazolyl, thiadiazolyl, pyrazolyl, isoxazolyl, indazolyl, or benzimidazolyl.
10. (Original) The compound of claim 1, wherein  $R^4$  is an optionally substituted phenyl group.
11. (Original) The compound of claim 8, wherein each occurrence of Z is independently a bond or a  $C_{1-4}$  alkylidene chain wherein one methylene unit of Z is optionally replaced by -O-, -S-, -SO<sub>2</sub>-, or -NH-; and each occurrence of  $R^5$  is independently hydrogen,  $C_{1-6}$  aliphatic, halogen, NO<sub>2</sub>, OR, N(R)<sub>2</sub>, or optionally substituted phenyl, pyridyl, or pyrimidinyl.
12. (Previously presented) The compound of claim 8, wherein each occurrence of  $ZR^5$  is independently Cl, F, Br, methyl, ethyl, t-butyl, isopropyl, cyclopropyl, nitro, CN, OMe, OEt, CF<sub>3</sub>, NH<sub>2</sub>, phenyl, benzyl, benzyloxy, OH, methylenedioxy, SO<sub>2</sub>NH<sub>2</sub>, CONH<sub>2</sub>, CO<sub>2</sub>Me, phenoxy, O-pyridinyl, SO<sub>2</sub>phenyl, nitrophenoxy, aminophenoxy, S-dimethylpyrimidine, NHphenyl, NH-methoxyphenyl, pyridinyl, phenol, chloro-fluoro-phenyl, dimethylaminophenyl, CF<sub>3</sub>-phenyl, dimethylphenyl, chlorophenyl, fluorophenyl, methoxyphenoxy, chlorophenoxy, ethoxyphenoxy, and fluorophenoxy.
13. (Original) The compound of claim 1, wherein  $(U)_pR^U$  and  $(V)_qR^V$  are each independently hydrogen, halogen, NO<sub>2</sub>, CN, OR, SR or N(R)<sub>2</sub>, or  $C_{1-4}$ aliphatic optionally substituted with oxo, OR, SR, N(R)<sub>2</sub>, halogen, NO<sub>2</sub> or CN.


Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936

14. (Original) The compound of claim 1, wherein  $(U)_pR^U$  and  $(V)_qR^V$  are each independently hydrogen, Me, OH, or OMe.

15. (Original) The compound of claim 1, wherein  $W^1$  is N or CH and compounds have the structure of Formula Ia or Ib:




Ia




Ib

or a pharmaceutically acceptable salt thereof.

16. (Previously presented) The compound of claim 15, wherein  $R^4$  is an optionally substituted phenyl group and compounds have the structure of Formula IIa or IIb:



IIa





IIb

or a pharmaceutically acceptable salt thereof.



17. (Previously presented) The compound of claim 16, wherein  $R^3$  is hydrogen, and compounds have the structure of Formula IIIa or IIIb:

Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936



or a pharmaceutically acceptable salt thereof.

18. (Previously presented) The compound of claim 16, wherein  $R^3$  is hydrogen, and  $R^1$  and  $R^2$  taken together form the heterocyclic moiety of formula (a) and compounds have the structure of Formula IVa or IVb:



or a pharmaceutically acceptable salt thereof.

19. (Previously presented) The compound of claim 15, wherein  
 i)  $R^1$  and  $R^2$  taken together form the heterocyclic moiety of formula (a); where  $R^X$  is defined according to one of the following groups:

- (a) hydrogen or optionally substituted  $C_{1-6}$ aliphatic;
- (b) hydrogen, methyl, ethyl, propyl, n-butyl, tert-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl,  $C_{1-6}$ alkyl substituted with  $N(R)_2$ , or  $C_{1-6}$ alkyl substituted with  $Ar^1$ ; or

Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

(c) hydrogen, methyl, or  $C_{1-2}$  alkyl substituted with a group selected from optionally substituted phenyl, pyridyl, morpholino, piperidiny, or piperazinyl.

ii)  $R^3$  is defined according to one of the following groups:

(a) hydrogen, halogen, QR or  $QAr^1$ , wherein Q is a  $C_{1-3}$  alkylidene chain wherein one methylene unit of Q is optionally replaced by -O-, -S-, -NHCO-, or -NR-, and  $Ar^1$  is an optionally substituted 5-6 membered saturated, partially unsaturated, or fully unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

(b) hydrogen, OH,  $OCH_3$ ,  $OCH_2CH_3$ ,  $NHCOMe$ ,  $NH_2$ ,  $NH(C_{1-4} \text{ aliphatic})$ ,  $N(C_{1-4} \text{ aliphatic})_2$ ,  $O(CH_2)_2$  morpholin-4-yl,  $O(CH_2)_2NH_2$ ,  $O(CH_2)_2NH(C_{1-4} \text{ aliphatic})$ ,  $O(CH_2)_2N(C_{1-4} \text{ aliphatic})_2$ , bromo, chloro, or fluoro; or

(c) hydrogen;

iii)  $R^4$  is defined according to one of the following groups:

(a) a 6-membered saturated, partially unsaturated, or aryl ring having 0-3 nitrogens, a 9-10 membered bicyclic aryl ring having 0-2 nitrogens, or a 5 membered heteroaryl ring having 2-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is optionally substituted with  $(ZR^5)_m$ ;

(b) an optionally substituted ring selected from phenyl, cyclohexyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, thiazolyl, thiadiazolyl, pyrazolyl, isoxazolyl, indazolyl, or benzimidazolyl, wherein said ring is optionally substituted with  $(ZR^5)_m$ ; or

(c) an optionally substituted phenyl group, wherein said phenyl group is optionally substituted with  $(ZR^5)_m$ ;

iv)  $W^1$ ,  $W^2$  and  $W^3$  are defined according to one of the following groups:

(a)  $W^1$  is nitrogen or CH,  $W^2$  is nitrogen or  $C-(U)_pR^U$ , and  $W^3$  is nitrogen or  $C-(V)_qR^V$ ;

Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936

- (b)  $W^1$  is nitrogen or CH,  $W^2$  is  $C-(U)_pR^U$ , and  $W^3$  is  $C-(V)_qR^V$ ; or
- (c)  $W^1$  is nitrogen or CH and  $W^2$  and  $W^3$  are each CH; and
- v)  $(U)_pR^U$  and  $(V)_qR^V$  groups are defined according to one of the following groups:
  - (a) hydrogen, halogen,  $NO_2$ , CN, OR, SR or  $N(R)_2$ , or  $C_{1-4}$ aliphatic optionally substituted with oxo, OR, SR,  $N(R)_2$ , halogen,  $NO_2$  or CN;
  - (b) hydrogen, Me, OH, OMe or  $N(R)_2$ ; or
  - (c) both  $(U)_pR^U$  and  $(V)_qR^V$  are hydrogen.

20. (Previously presented) The compound of any one of claims 16, 17, 18 or 19, wherein each occurrence of Z is independently a bond or a  $C_{1-4}$  alkylidene chain wherein one methylene unit of Z is optionally replaced by -O-, -S-, - $SO_2$ -, or -NH-; and each occurrence of  $R^5$  is independently hydrogen,  $C_{1-6}$  aliphatic, halogen,  $NO_2$ , OR,  $N(R)_2$ , or optionally substituted phenyl, pyridyl, and pyrimidinyl

21. (Previously presented) The compound of claim 20, wherein each occurrence of  $ZR^5$  is independently Cl, F, Br, methyl, ethyl, t-butyl, isopropyl, cyclopropyl, nitro, CN, OMe, OEt,  $CF_3$ ,  $NH_2$ , phenyl, benzyl, benzyloxy, OH, methylenedioxy,  $SO_2NH_2$ ,  $CONH_2$ ,  $CO_2Me$ , phenoxy, O-pyridinyl,  $SO_2$ phenyl, nitrophenoxy, aminophenoxy, S-dimethylpyrimidine, NHphenyl, NH-methoxyphenyl, pyridinyl, phenol, chloro-fluoro-phenyl, dimethylaminophenyl,  $CF_3$ -phenyl, dimethylphenyl, chlorophenyl, fluorophenyl, methoxyphenoxy, chlorophenoxy, ethoxyphenoxy, or fluorophenoxy.













22. (Previously presented) The compound of claim 18 having the formula IVa, wherein  $R^X$  is hydrogen or optionally substituted  $C_{1-6}$ aliphatic; m is 0, 1 or 2; and  $ZR^5$  is Cl, F, Br, methyl, ethyl, t-butyl, isopropyl, cyclopropyl, nitro, CN, OMe, OEt,  $CF_3$ ,  $NH_2$ , phenyl, benzyl, benzyloxy, OH, methylenedioxy,  $SO_2NH_2$ ,  $CONH_2$ ,  $CO_2Me$ , phenoxy, O-pyridinyl,  $SO_2$ phenyl, nitrophenoxy, aminophenoxy, S-dimethylpyrimidine, NHphenyl, NH-methoxyphenyl, pyridinyl, phenol, chloro-fluoro-phenyl, dimethylaminophenyl,  $CF_3$ -phenyl,




Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

dimethylphenyl, chlorophenyl, fluorophenyl, methoxyphenoxy, chlorophenoxy, ethoxyphenoxy, or fluorophenoxy.


23. (Previously presented) The compound of claim 1, selected from one of the following compounds:

**IVa-1****IVa-2****IVa-3****IVa-4****IVa-5****IVa-6****IVa-7****IVa-8****IVa-9****IVa-10****IVa-11****IVa-12**


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVa-13




IVa-14




IVa-15




IVa-16




IVa-17




IVa-18




IVa-19




IVa-20




IVa-21



IVa-22
















IVa-23




IVa-24


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

**IVa-25****IVa-26****IVa-27****IVa-28****IVa-29****IVa-30****IVa-31****IVa-32****IVa-33****IVa-34****IVa-35****IVa-36****IVa-37**


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVa-38




IVa-39




IVa-40




IVa-41




IVa-42




IVa-43




IVa-44




IVa-45




IVa-46



IVa-47













IVa-48












IVa-49

Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

**IVa-50****IVa-51****IVa-52****IVa-53****IVa-54****IVa-55****IVa-56****IVa-57****IVa-58****IVa-59**


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

**IVa-60****IVa-61****IVa-62****IVa-63****IVa-64****IVa-65****IVa-66****IVa-67****IVa-68**


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-7




IVb-8




IVb-9




IVb-10




IVb-11




IVb-12




IVb-13




IVb-14




IVb-15



IVb-16




IVb-17




IVb-18




Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-19




IVb-20




IVb-21




IVb-22




IVb-23




IVb-24




IVb-25




IVb-26




IVb-27



IVb-28




IVb-29



IVb-30


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-31

IVb-32


IVb-33




IVb-34




IVb-35




IVb-36




IVb-37




IVb-38




IVb-39



IVb-40




IVb-41




IVb-42


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-43




IVb-44




IVb-45




IVb-46




IVb-47




IVb-48




IVb-49



IVb-50




IVb-51




IVb-52


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-53




IVb-54




IVb-55




IVb-56




IVb-57




IVb-58




IVb-59



IVb-60




IVb-61




IVb-62


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-63




IVb-64




IVb-65




IVb-66




IVb-67




IVb-68



IVb-69




IVb-70



IVb-71

Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936



or

IVb-72.

24. (Original) A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

25-27. (Canceled)

28. (Currently amended) A method of treating or lessening the severity of a disease or disorder selected from an allergic or type I hypersensitivity reaction, asthma, transplant rejection, graft versus host disease, or rheumatoid arthritis, ~~or leukemia~~, comprising administering to a subject in need thereof a compound of claim 1 or a composition comprising said compound.

29. (Currently amended) The method of claim 28, comprising the further step of administering to said patient an additional therapeutic agent selected from a ~~chemotherapeutic or anti-proliferative agent~~, a treatment for asthma, an anti-inflammatory agent, or an immunomodulatory or immunosuppressive agent, wherein:  
said additional therapeutic agent is appropriate for the disease being treated; and  
said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**